Effect of Subarachnoid Hyperbaric Bupivacaine on Mean Arterial Pressure in Obese Pregnant Patients Undergoing Cesarean Section

This clinical trial is investigating how a specific anesthetic called subarachnoid hyperbaric bupivacaine affects blood pressure in obese pregnant women who are undergoing a C-section. The trial focuses on women who are at least 37 weeks pregnant, have a BMI of 30 or above, and have babies that are doing well. This research is important because keeping blood pressure stable during surgery is crucial for the safety of both the mother and the baby. Understanding the effects of this anesthetic could improve the care provided during cesarean sections for obese patients. In the study, participants receive anesthesia through a mixed technique that involves both epidural and subarachnoid blocks. The procedure begins with a thorough pre-anesthetic evaluation and monitoring of vital signs. Patients are randomly assigned to receive different doses of the anesthetic, either 5 mg or 10 mg, to observe its effect on mean arterial pressure (MAP). The researchers monitor vital signs frequently during surgery and assess sensory and motor blockades. They also record nausea and vomiting incidents, and evaluate the newborn's condition using the Apgar score. Data collected will help determine if the anesthetic dose affects blood pressure and overall surgical outcomes, providing insights into safer anesthetic practices for obese pregnant patients.